Daclizumab (an anti-IL2 receptor antibody for transplant rejection) and bevacizumab (an anti-vascular endothelial growth factor (VEGF) antibody for metastatic colorectal cancer) are the two known humanized antibodies approved by the FDA in 1997 and 2004, respectively [32]. Here, VEGFA is linked to metastatic colorectal cancer.